J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus
You may also be interested in...
J&J’s Broad Device Portfolio Eclipses Lackluster Stent Sale Growth
Johnson & Johnson's medical device and diagnostics revenue grew 11.8% in the second quarter to $4.06 bil., despite a negligible increase in U.S. Cypher drug-eluting stent revenue from the year-ago period
J&J’s Broad Device Portfolio Eclipses Lackluster Stent Sale Growth
Johnson & Johnson's medical device and diagnostics revenue grew 11.8% in the second quarter to $4.06 bil., despite a negligible increase in U.S. Cypher drug-eluting stent revenue from the year-ago period
Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities
Johnson & Johnson/Cordis' inability to provide timely failure analysis reports of Cypher-related thrombosis complaints is one of several GMP violations cited in an April 1 FDA 1warning letter